Emerging drugs for the treatment of irritability associated with autism spectrum disorder
ReviewHumans
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Which emerging medications help irritability in autism spectrum disorder, drawn from randomised controlled trials, including palmitoylethanolamide as an adjunct to risperidone
What the authors reported
This review found:
- After risperidone and aripiprazole, memantine monotherapy may be beneficial.
- Palmitoylethanolamide and 15 other agents given as adjuncts to risperidone, plus clonidine and methylphenidate, outperformed placebo in trials.
- All were reported as safe and tolerable.
- Sample size, follow-up and effect size mean further studies are needed, the authors say.
Limits of this study
A narrative expert review; the abstract gives no trial sizes, PEA doses or effect sizes. Funding and conflicts not stated in the abstract.
Source
PubMed 38296815 · doi:10.1080/14728214.2024.2313650
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.